Subject(s)
Acetamides/pharmacology , Anti-Bacterial Agents/pharmacology , Cross Infection/epidemiology , Disease Outbreaks , Drug Resistance, Bacterial , Oxazolidinones/pharmacology , Staphylococcal Infections/epidemiology , Staphylococcus/drug effects , Adult , Aged , Cross Infection/microbiology , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Female , Humans , Intensive Care Units , Linezolid , Male , Microbial Sensitivity Tests , Middle Aged , Molecular Sequence Data , Sequence Analysis, DNA , Staphylococcal Infections/microbiology , Staphylococcus/classification , Staphylococcus/genetics , Staphylococcus/isolation & purificationABSTRACT
Within the minimal supersymmetric extension of the standard model, the mass of the light CP-even Higgs boson is computed to three-loop accuracy, taking into account the next-to-next-to-leading order effects from supersymmetric quantum chromodynamics. We consider two different scenarios for the mass hierarchies of the supersymmetric spectrum. Our numerical results amount to corrections of about 500 MeV, which is of the same order as the experimental accuracy expected at the CERN Large Hadron Collider.
ABSTRACT
An outbreak of infection with vancomycin-resistant Enterococcus faecium occurred at Hotel-Dieu Hospital (Clermont-Ferrand, France). A case-control study was performed in the infectious diseases and hematology units of the hospital. Urinary catheter use (odds ratio [OR], 12 [95% confidence interval {CI}, 1.5-90]; P<.02), prior exposure to a third-generation cephalosporin (OR, 22 [95% CI, 3-152]; P=.002), and prior exposure to antianaerobials (OR, 11 [95% CI, 1.5-88]; P<.02) were independently predictive of vancomycin-resistant Enterococcus faecium carriage.
Subject(s)
Disease Outbreaks , Enterococcus faecium/pathogenicity , Gram-Positive Bacterial Infections/epidemiology , Vancomycin Resistance , Electrophoresis, Gel, Pulsed-Field , Enterococcus faecium/isolation & purification , Female , France/epidemiology , Hospitals, University , Humans , Male , Middle AgedABSTRACT
Between January 1989 and May 1991, 97 patients were treated with interleukin 2 in the Oncology Department of the Avicenne Hospital (Bobigny, France). IL 2 was given over 5 days by continuous infusion through an implantable port. Ten patients (4 males, 6 females), mean age 46 years (36-67) with various cancers (breast 3, kidney 1, melanoma 1, colorectal 5), developed infection: 4 local infections around the port, 1 phlebitis, 4 septicemias, 1 bacteremia were observed. In 9 cases blood cultures were positive: Staphylococcus aureus 5, Staphylococcus epidermidis 3, Streptococcus G 1. In 5 cases the same pathogen was isolated from the port and from the blood. The mean leucocyte count was 10,627/mm3 at the time of infection. The delay between the beginning of interleukin 2 treatment and the infection was 3 months. The mean dose of IL 2 administered before infection was 456 million IU. In all cases infection was controlled without lethal complication by antibiotics and catheter removal. This high incidence (8 percent) of staphylococcal infection is partly due to the skin toxicity of IL 2 and to depressed neutrophil chemotactic response. Prophylactic antibiotics are warranted during IL 2 intravenous therapy.
